2005
NAP: Research and Development of a Peptide Derived from Activity‐Dependent Neuroprotective Protein (ADNP)
Gozes I, Morimoto B, Tiong J, Fox A, Sutherland K, Dangoor D, Holser‐Cochav M, Vered K, Newton P, Aisen P, Matsuoka Y, van Dyck C, Thal L. NAP: Research and Development of a Peptide Derived from Activity‐Dependent Neuroprotective Protein (ADNP). CNS Neuroscience & Therapeutics 2005, 11: 353-368. PMID: 16614735, PMCID: PMC6741706, DOI: 10.1111/j.1527-3458.2005.tb00053.x.Peer-Reviewed Original ResearchConceptsActivity-dependent neuroprotective proteinIntranasal administrationClinical trialsNeuroprotective proteinPhase Ia clinical trialPhase I clinical trialApolipoprotein E deficiencyFurther clinical developmentAdverse side effectsBeta-amyloid peptideAscending dosesElectrical blockadeCardiopulmonary testSingle doseCholinergic toxicityHead injuryIntravenous formulationCognitive dysfunctionDose toxicityElderly volunteersActive doseE deficiencySide effectsAnimal modelsClinical development
1997
The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys
Arnsten A, Lin C, Van Dyck C, Stanhope K. The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys. Neurobiology Of Aging 1997, 18: 21-28. PMID: 8983029, DOI: 10.1016/s0197-4580(96)00162-5.Peer-Reviewed Original ResearchConceptsVisual object discriminationObject discriminationFine motor tasksMotor tasksCognitive-enhancing effectsMemory taskResponse taskCognitive performanceReceptor antagonistEnhanced acquisitionCognitive functionReliable improvementMarmoset researchAged monkeysTaskReversal conditionsWide dose rangeDiscriminationSide effectsLow dosesRhesus monkeysDose rangeAntagonistAcquisitionMonkeys